European Renal Association

And you can see here we had a number of secondary and exploratory endpoints looking at change in UPCr at different time points, a composite kidney failure endpoint, reduction in UPCr to greater than fifty percent from baseline, achieving certain UPCr targets, and patient-reported outcomes.

So what were the key results from the interim analysis? Well, these were data that were presented at the European Renal Association meeting in Glasgow in June.

And what you can see here is that blocking C5 with ravulosumab leads to a highly significant and clinically relevant reduction in proteinuria at week thirty-four.

You see a treatment effect of minus forty-three point four percent, i.e. forty-three point four percent greater reduction in proteinuria compared to the effect of placebo alone.

Now, I'll also note that ESC put out two brand-new guidelines at the meeting.

One is on managing cardiovascular disease and chronic kidney disease, and it was published with the European Renal Association.

And the other brand-new guideline is on cardiac rehabilitation.

So again, so much clinically relevant information at this conference, and I'm so grateful that you were able to join me to chat about it, Dr. Guzik.